You are here

Use and Outcomes of Antifibrinolytic Therapy in Patients Undergoing Cardiothoracic Surgery at 20 Academic Medical Centers in the United States

Karl Matuszewski, MS, PharmD; Robert Schoenhaus, PharmD; Mary Ellen Bonk, PharmD; James Lane, PharmD; and Michael Oinonen, PharmD, MPH
PDF version: 
Given the association between the use of aprotinin (Trasylol) and an increased risk of adverse events among cardiothoracic surgery patients, in contrast to a lack of elevated risk for aminocaproic acid and tranexamic acid, the authors suggest that hospitals examine their current patterns of use and perhaps restrict aprotinin for these patients to prevent major blood loss.